

GENSIGHT BIOLOGICS
A French Société Anonyme (corporation)
with share capital of 605,855.575 Euros
74 rue du Faubourg Saint Antoine
75012 Paris
751 164 757 - Paris Trade and Companies Registry

**NOMINEES TO THE BOARD OF DIRECTORS, GENERAL MEETING OF APRIL 12,
2018**

USUAL NAME: Bernard GILLY

OFFICES THAT EXPIRED IN THE LAST FIVE YEARS IN OTHER COMPANIES :

Bernard Gilly, Ph.D., one of our founders, has served as our Chief Executive Officer since our creation. From our creation through 2016, Dr. Gilly served as Chairman of our Board of Directors. From 2011 through 2014, Dr. Gilly served as Chief Executive Officer at Pixium Vision and from which date he has served as non-executive Chairman of the Board of Directors. Additionally, Mr. Gilly currently serves on the boards of Prophesee S.A. (formerly Chronocam) and Gecko Biomedical. Dr. Gilly received an engineering degree from École Nationale d'Agronomie and a Ph.D. from Université de Rennes.

OFFICES IN THE COMPANY:

Chief Executive Officer

NUMBER OF SHARES OF THE CORPORATION OWNED:

622,600

GENSIGHT BIOLOGICS
A French Société Anonyme (corporation)
with share capital of 605,855.575 Euros
74 rue du Faubourg Saint Antoine
75012 Paris
751 164 757 - Paris Trade and Companies Registry

**NOMINEES TO THE BOARD OF DIRECTORS, GENERAL MEETING OF APRIL 12,
2018**

USUAL NAME: Michael WYZGA

OFFICES THAT EXPIRED IN THE LAST FIVE YEARS IN OTHER COMPANIES:

Michael Wyzga has served as a director since 2015 and as our Chairman since March 2016. Mr. Wyzga is currently the President of MSW Consulting, Inc., a private company focused on strategic biotechnology consulting. Prior to that, Mr. Wyzga served as President and Chief Executive Officer and a member of the board of directors of Radius Health, Inc. (Nasdaq: RDUS), a biopharmaceutical company, from December 2011 until November 2013. Since February 2014, Mr. Wyzga has served as a member of the board of directors of Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company, where he is also a member of the compensation committee and chair of the audit committee. Since February 2013, Mr. Wyzga has also served as a member of the board of directors and chair of the audit committee of OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED) a biopharmaceutical company. Since February 2015, Mr. Wyzga has also served as a member of the board of directors of Exact Sciences Corporation (Nasdaq: EXAS), a medical technology company, where he is also a member of the audit and compensation committees. Mr. Wyzga received an M.B.A. from Providence College and a B.S. from Suffolk University.

OFFICES IN THE COMPANY:

Chairman of the Board of Directors

NUMBER OF SHARES OF THE CORPORATION OWNED:

0